These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 8140563)

  • 1. [The elderly healthy volunteer: a necessity].
    Allain H; Le Coz F; Bureau M
    Therapie; 1993; 48(3):239-42. PubMed ID: 8140563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phased approach to clinical testing: criteria for progressing from Phase I to Phase II to Phase III studies.
    André FE; Foulkes MA
    Dev Biol Stand; 1998; 95():57-60. PubMed ID: 9855414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Anticancer chemotherapy in the elderly: a review of the literature].
    Debrix I; Avenin D; André T; Abbas F; Gligorov J; Milleron B; Lotz JP; Becker A
    Bull Cancer; 2008 May; 95 FMC Onco():F37-43. PubMed ID: 18511365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the outcome of phase III trials using phase II data: a case study of clinical trial simulation in late stage drug development.
    De Ridder F
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):235-41. PubMed ID: 15733220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical trial design in metastatic breast cancer: a commentary.
    Levine M
    Can J Oncol; 1995 Dec; 5 Suppl 1():40-2. PubMed ID: 8853523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Methodological approaches of clinical studies with targeted therapies].
    Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
    Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
    Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
    Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The strategy of combination phase I/II study].
    Murakami H; Ohe Y; Saijo N
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2151-4. PubMed ID: 11103251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical assessment of international clinical development programmes for new antihypertensive drugs.
    Ménard J
    J Hypertens Suppl; 1993 Dec; 11(5):S39-46. PubMed ID: 8158432
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantifying emerging drugs for very rare conditions.
    Miles KA; Packer C; Stevens A
    QJM; 2007 May; 100(5):291-5. PubMed ID: 17456610
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 25-year review of sequential methodology in clinical studies.
    Todd S
    Stat Med; 2007 Jan; 26(2):237-52. PubMed ID: 17139691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical trials part II.
    Burgess G
    Surviv News (Atlanta Ga); 2002 Jul; ():12. PubMed ID: 12238473
    [No Abstract]   [Full Text] [Related]  

  • 15. Are bisphosphonates the suitable anticancer drugs for the elderly?
    Santini D; Fratto ME; Galluzzo S; Vincenzi B; Tonini G
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):83-94. PubMed ID: 18692400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigational drug tracking: phases I-III and NDA submissions--Part II.
    Grant KL
    Hosp Pharm; 1994 Oct; 29(10):900, 902-4, 906-11 passim. PubMed ID: 10137850
    [TBL] [Abstract][Full Text] [Related]  

  • 17. How pharmacogenomics will impact the federal regulation of clinical trials and the new drug approval process.
    Binzak BA
    Food Drug Law J; 2003; 58(1):103-27. PubMed ID: 12739592
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rationale and design of the enoximone clinical trials program.
    Lowes BD; Shakar SF; Metra M; Feldman AM; Eichhorn E; Freytag JW; Gerber MJ; Liard JF; Hartman C; Gorczynski R; Evans G; Linseman JV; Stewart J; Robertson AD; Roecker EB; Demets DL; Bristow MR
    J Card Fail; 2005 Dec; 11(9):659-69. PubMed ID: 16360960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug research: from the idea to the product.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.